Clinicopathological features of human brainstem gliomas

Brain Tumor Pathology

Volumn 30, Issue 1, 2013, Pages 1-7

  Oka, Hidehiro ^a   Utsuki, Satoshi ^a   Tanizaki, Yoshinori ^a   Hagiwara, Hiroyuki ^a   Miyajima, Yoshiteru ^a   Sato, Kimitoshi ^a   Kusumi, Mari ^a   Kijima, Chihiro ^a   Fujii, Kiyotaka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Astrocytoma; Brainstem glioma; IDH1; MGMT; p53

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

ADOLESCENT; ADULT; ANASTOMOSIS; ARTICLE; ASTROCYTOMA; BRAIN STEM TUMOR; BRAIN SURGERY; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDULLA OBLONGATA; MESENCEPHALON; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE HYDROCEPHALUS; PONTINE GLIOMA; PRESCHOOL CHILD; SCHOOL CHILD; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; INFANT; ISOCITRATE DEHYDROGENASE; MALE; MEDULLA OBLONGATA; MESENCEPHALON; MIDDLE AGED; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873060791     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-012-0099-8     Document Type: Article

References (29)

1. Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241-248
2. Guillamo JS, Monjour A, Taillandier L et al (2001) Brainstem gliomas in adults: prognostic factors and classification. Brain 124:2528-2539
3. Leach PA, Estlin EJ, Coope DJ et al (2008) Diffuse brainstem gliomas in children: should we or shouldn't we biopsy? Br J Neurosurg 22:619-624
4. Puputti M, Tynninen O, Sihto H et al (2006) Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 4:927-934
5. Di Sapio A, Morra I, Pradotto M et al (2002) Molecular genetic changes in a series of neuroepithelial tumors of childhood. J Neurooncol 59:117-122
6. Wong KK, Tsang YT, Chang YM et al (2006) Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res 66:11172-11178
7. Sung T, Miller DC, Hayes RL et al (2000) Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10:249-259
8. Liang ML, Ma J, Ho M et al (2008) Tyrosine kinase expression in pediatric high-grade astrocytoma. J Neurooncol 87:247-253
9. Cheng Y, Ng HK, Zhang SF et al (1999) Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 30:1284-1290
10. Badhe PB, Chauhan PP, Mehta NK (2004) Brainstem gliomas - a clinicopathological study of 45 cases with p53 immunohistochemistry. Indian J Cancer 41:170-174
11. Louis DN, Rubio MP, Correa KM et al (1993) Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 52:507-515
12. Zhang S, Feng X, Koga H et al (1993) p53 gene mutations in pontine gliomas of juvenile onset. Biochem Biophys Res Commun 196:851-857
13. Sure U, Ruedi D, Tachibana O et al (1997) Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 56:782-789
14. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
15. Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602
16. Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7-11
17. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474
18. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
19. Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153
20. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
21. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncol 11:341-347
22. Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007
23. Thorarinsdottir HK, Santi M, McCarter R et al (2008) Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res 14:3386-3394
24. Nakamura M, Shimada K, Ishida E et al (2007) Molecular pathogenesis of pediatric astrocytic tumors. Neuro-Oncol 9:113-123
25. Geoerger B, Morland B, Ndiaye A et al (2009) Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer 45:2236-2238
26. Wakabayashi T, Natsume A, Hatano H et al (2009) p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery 64:455-461
27. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
28. van den Bent MJ, Dubbink HJ, Sanson M et al (2009) MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27:5881-5886
29. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880